Hemimegalencephaly is a hamartomatous malformation of one hemisphere. Functional hemispherectomy, the definitive treatment, is associated with significant morbidity and mortality in early infancy. Dysregulation of the mTOR pathway can result in malformations of cortical development, and mTOR inhibitors can effectively reduce seizures in tuberous sclerosis complex. We report a 6-day-old female with hemimegalencephaly and frequent seizures despite 9 antiseizure medications. At 3 months of age, while awaiting hemispherectomy, an mTOR inhibitor, rapamycin, was initiated by the neurologist. After 1 week of treatment, there was >50% reduction in seizures and total seizure burden, and after 2 weeks, development improved, resulting in deferral of surgery by 2.5 months with an increased body weight. Pathology demonstrated cortical dysplasia with upregulation of the mTOR pathway. Deep-sequencing of brain tissue demonstrated 16% mosaicism for a pathogenic de novo MTOR gene mutation. This case exemplifies how mTOR inhibitors could be considered for seizure reduction in patients with hemimegalencephaly while awaiting surgery.
TakashimaSChanFBeckerLE. Aberrant neuronal development in hemimegalencephaly: immunohistochemical and Golgi studies. Pediatr Neurol. 1991;7:275–280.
2.
Flores-SarnatLSarnatHBDavila-GutierrezG. Hemimegalencephaly: part 2. Neuropathology suggests a disorder of cellular lineage. J Child Neurol. 2003;18:776–785.
3.
O’KuskyJRAkersMAVintersHV. Synaptogenesis in hemimegalencephaly: the numerical density of asymmetric and symmetric synapses in the cerebral cortex. Acta Neuropathol. 1996;92:156–163.
4.
PisaniFCerminaraCFuscoC. Neonatal status epilepticus vs recurrent neonatal seizures: clinical findings and outcome. Neurology. 2007;69:2177–2185.
5.
KharoshankayaLStevensonNJLivingstoneV. Seizure burden and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy. Dev Med Child Neurol. 2016;58:1242–1248.
6.
PinchefskyEFHahnCD. Outcomes following electrographic seizures and electrographic status epilepticus in the pediatric and neonatal ICUs. Curr Opin Neurol. 2017;30:156–164.
7.
PayneETZhaoXYFrndovaH. Seizure burden is independently associated with short term outcome in critically ill children. Brain. 2014;137:1429–1438.
8.
AbendNSWagenmanKLBlakeTP. Electrographic status epilepticus and neurobehavioral outcomes in critically ill children. Epilepsy Behav. 2015;49:238–244.
9.
LeeJHHuynhMSilhavyJL. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012;44:941–945.
10.
D’GamaAMGengYCoutoJA. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol. 2015;77:720–725.
11.
HanaiSSukigaraSDaiH. Pathologic active mTOR mutation in brain malformation with intractable epilepsy leads to cell-autonomous migration delay. Am J Pathol. 2017;187:1177–1185.
12.
SulisMLParsonsR. PTEN: from pathology to biology. Trends Cell Biol. 2003;13:478–483.
13.
PuffenbergerEGStraussKARamseyKE. Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5. Brain. 2007;130:1929–1941.
14.
CrinoPB. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med. 2011;17:734–742.
15.
LeeDY. Roles of mTOR signaling in brain development. Exp Neurobiol. 2015;24:177–185.
16.
PópuloHLopesJMSoaresP. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13:1886–1918.
17.
ZengLHXuLGutmannDH. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63:444–453.
18.
MeikleLPollizziKEgnorA. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28:5422–5432.
19.
SarnatHFlores-SarnatLCrinoP. Hemimegalencephaly: foetal tauopathy with mTOR hyperactivation and neuronal lipidosis. Folia Neuropathol. 2012;50:330–345.
20.
ShlienACampbellBBde BorjaR. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015;47:257–262.
21.
CampbellBBLightNFabrizioD. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171:1042–1056.e1010.
22.
D’AgostinoMDBastosAPirasC. Posterior quadrantic dysplasia or hemi-hemimegalencephaly: a characteristic brain malformation. Neurology. 2004;62:2214–2220.
23.
MirzaaGMContiVTimmsAE. Characterisation of mutations of the phosphoinositide-3-kinase regulatory subunit, PIK3R2, in perisylvian polymicrogyria: a next-generation sequencing study. Lancet Neurol. 2015;14:1182–1195.
24.
JaworskiJSpanglerSSeeburgDP. Control of dendritic arborization by the phosphoinositide-3’-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci. 2005;25:11300–11312.
25.
KumarVZhangMXSwankMW. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci. 2005;25:11288–11299.
26.
CrinoPB. mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb Perspect Med. 2015;5.
27.
LimJSKimWIKangHC. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med. 2015;21:395–400.
28.
GotoJTalosDMKleinP. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci U S A. 2011;108:E1070–1079.
29.
ZengLHRensingNRZhangB. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet. 2011;20:445–454.
30.
GalanopoulouASGorterJACepedaC. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia. 2012;53:1119–1130.
31.
SunnenCNBrewsterALLugoJN. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia. 2011;52:2065–2075.
32.
LjungbergMCSunnenCNLugoJN. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech. 2009;2:389–398.
33.
NguyenLHBrewsterALClarkME. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia. Epilepsia. 2015;56:636–646.
34.
FranzDNBelousovaESparaganaS. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014;15:1513–1520.
35.
FranzDNBelousovaESparaganaS. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One. 2016;11:e0158476.
36.
AwFGoyerIRaboissonMJ. Accelerated cardiac rhabdomyoma regression with everolimus in infants with tuberous sclerosis complex. Pediatr Cardiol. 2017;38:394–400.
37.
FrenchJALawsonJAYapiciZ. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153–2163.
38.
CuratoloPFranzDNLawsonJ. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. Lancet Child Adolesc Health. 2018;2:495–504.
39.
KruegerDACapalJKCuratoloP. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. Eur J Paediatr Neurol. 2018;6:1066–1073.
40.
US Food and Drug Administration. FDA approves everolimus for tuberous sclerosis complex-associated partial-onset seizures. 2018.
41.
TiretLNivocheYHattonF. Complications related to anaesthesia in infants and children. A prospective survey of 40240 anaesthetics. Br J Anaesth. 1988;61:263–269.
DorferCOchiASneadOC3rd. Functional hemispherectomy for catastrophic epilepsy in very young infants: technical considerations and complication avoidance. Child’s Nervous Syst. 2015;31:2103–2109.
